文献速递认知障碍与痴呆

他汀类药物类型与阿尔茨海默病发病风险的比较效果

Comparative effect of statins on the risk of incident Alzheimer disease.
PubMed 文献 · Neurology · 2017-12-15

基于英国临床实践研究数据链的回顾性队列研究,纳入1994至2012年间新处方他汀的≥60岁患者465,085例,随访至2015年。与合成他汀相比,真菌来源他汀与AD风险升高相关(HR 1.09, 95%CI 1.03-1.15);亲脂性他汀较亲水性他汀AD风险更高(HR 1.18, 95%CI 1.09-1.27);他汀效力未显著改变AD风险。

要点

  • 真菌来源他汀较合成他汀AD风险轻度升高(HR 1.09)。
  • 亲脂性他汀较亲水性他汀AD风险更高(HR 1.18)。
  • 他汀效力与AD风险无显著关联(HR 1.03, 95%CI 0.98-1.08)。

核心结论

  • 真菌来源和亲脂性他汀与合成和亲水性他汀相比,并未降低AD发病率,反而风险轻度升高。

研究设计与样本

  • 基于英国临床实践研究数据链的回顾性队列研究,纳入1994年1月1日至2012年12月31日新处方他汀的≥60岁患者,随访至2015年3月31日。

主要发现

  • 共纳入465,085例他汀使用者,随访2,891,268人年,期间7,669例发生AD,粗发病率为2.65/1000人年(95%CI 2.59-2.71)。
  • 与合成他汀相比,真菌来源他汀的AD风险HR为1.09(95%CI 1.03-1.15)。
  • 与亲水性他汀相比,亲脂性他汀的AD风险HR为1.18(95%CI 1.09-1.27)。
  • 他汀效力与AD风险无关,调整后HR为1.03(95%CI 0.98-1.08)。

临床怎么用

  • 临床选择他汀时,不应以降低AD风险为目的优先选用真菌来源或亲脂性他汀。

局限性

  • 观察性设计可能存在残余混杂,他汀分类基于处方记录,AD诊断可能受监测偏倚影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether fungus-derived statins are associated with a lower risk of incident Alzheimer disease (AD) compared with synthetic statins using real-world clinical practice data. METHODS: We identified a population-based retrospective cohort of patients aged ≥60 years newly prescribed a statin between January 1, 1994, and December 31, 2012, and followed until March 31, 2015, using the UK Clinical Practice Research Datalink. Statins were consecutively classified according to their type, lipophilicity, and potency. For each group, we calculated the crude AD incidence rates per 1,000 person-years. Time-dependent Cox proportional hazards models adjusted for propensity score deciles were used to estimate hazard ratios (HRs) with 95% confidence interval (CIs) of incident AD associated with different statin categories. RESULTS: Over the 18-year study period, we identified 465,085 statin users, including 7,669 patients who developed AD during 2,891,268 person-years of follow-up (incidence rate 2.65 [95% CI 2.59-2.71] per 1,000 person-years). Compared to synthetic, fungus-derived statins were associated with an increased risk of AD (HR 1.09, 95% CI 1.03-1.15). Lipophilic statins also were associated with higher AD risk (HR 1.18, 95% CI 1.09-1.27) compared to hydrophilic statins, while statin potency did not modify the risk of AD (adjusted HR 1.03, 95% CI 0.98-1.08). The risk was further reduced in sensitivity analyses. CONCLUSION: Fungus-derived and lipophilic statins were not associated with decreased incidence of AD compared to synthetic and hydrophilic statins. The modest variations in the risk of incident AD observed between statin characteristics needs to be evaluated in future studies on their possible heterogeneous neuroprotective effect.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sinyavskaya L, Gauthier S, Renoux C, et al. Comparative effect of statins on the risk of incident Alzheimer disease. Neurology. 2017. PMID: 29247073. doi:10.1212/WNL.0000000000004818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。